City-话题@MedSci

#City#

13篇内容 | 1234人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1941536, encodeId=de4719415366a, content=<a href='/topic/show?id=64c94e75a3' target=_blank style='color:#2F92EE;'>#City#</a>, objectTitle=Bioelectricity:电磁场可阻碍乳腺癌转移扩散!, objectType=article, longId=208639, objectId=ae76208639bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae76208639bc, replyNumber=0, likeNumber=101, createdTime=2021-10-02, rootId=0, userName=nakerunner, userId=0cd7162, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae76208639bc, moduleTitle=Bioelectricity:电磁场可阻碍乳腺癌转移扩散!, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae76208639bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1941537, encodeId=feb7194153e8e, content=<a href='/topic/show?id=64c94e75a3' target=_blank style='color:#2F92EE;'>#City#</a>, objectTitle=City of Hope与Israelita Albert Einstein签署协议以推动拉美地区的癌症治疗, objectType=article, longId=209625, objectId=fb6b20962556, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb6b20962556, replyNumber=0, likeNumber=98, createdTime=2021-07-11, rootId=0, userName=nakerunner, userId=0cd7162, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb6b20962556, moduleTitle=City of Hope与Israelita Albert Einstein签署协议以推动拉美地区的癌症治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb6b20962556)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1941534, encodeId=5b11194153491, content=<a href='/topic/show?id=64c94e75a3' target=_blank style='color:#2F92EE;'>#City#</a>, objectTitle=City of Hope正在招募患者进行HPV相关癌症的人体T细胞试验, objectType=article, longId=177802, objectId=58ec1e780208, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58ec1e780208, replyNumber=0, likeNumber=80, createdTime=2019-09-27, rootId=0, userName=nakerunner, userId=0cd7162, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58ec1e780208, moduleTitle=City of Hope正在招募患者进行HPV相关癌症的人体T细胞试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58ec1e780208)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1941535, encodeId=cb8519415355d, content=<a href='/topic/show?id=64c94e75a3' target=_blank style='color:#2F92EE;'>#City#</a>, objectTitle=礼来的GLP-1受体激动剂Trulicity，获得FDA批准用于降低心血管风险, objectType=article, longId=188799, objectId=77e1188e9962, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77e1188e9962, replyNumber=0, likeNumber=77, createdTime=2020-11-03, rootId=0, userName=nakerunner, userId=0cd7162, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77e1188e9962, moduleTitle=礼来的GLP-1受体激动剂Trulicity，获得FDA批准用于降低心血管风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=77e1188e9962)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1941533, encodeId=13d71941533ae, content=<a href='/topic/show?id=64c94e75a3' target=_blank style='color:#2F92EE;'>#City#</a>, objectTitle=A novel Ruthenium(II) polypyridyl complex induces cytotoxicity, cell cycle arrest, apoptosis and DNA, objectType=article, longId=117031, objectId=7bbf11e031f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7bbf11e031f1, replyNumber=0, likeNumber=82, createdTime=2018-05-24, rootId=0, userName=nakerunner, userId=0cd7162, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7bbf11e031f1, moduleTitle=A novel Ruthenium(II) polypyridyl complex induces cytotoxicity, cell cycle arrest, apoptosis and DNA, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7bbf11e031f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1941532, encodeId=ee021941532ff, content=<a href='/topic/show?id=64c94e75a3' target=_blank style='color:#2F92EE;'>#City#</a>, objectTitle=ADA 2016：礼来每周一次降糖药Trulicity（度拉鲁肽）联合甘精胰岛素显著改善2型糖尿病患者血糖控制, objectType=article, longId=71031, objectId=ed04e103173, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed04e103173, replyNumber=0, likeNumber=85, createdTime=2016-12-11, rootId=0, userName=nakerunner, userId=0cd7162, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed04e103173, moduleTitle=ADA 2016：礼来每周一次降糖药Trulicity（度拉鲁肽）联合甘精胰岛素显著改善2型糖尿病患者血糖控制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed04e103173)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1941531, encodeId=3eb719415314e, content=<a href='/topic/show?id=64c94e75a3' target=_blank style='color:#2F92EE;'>#City#</a>, objectTitle=Symplicity HTN-3 后时代：经导管去肾交感神经术（RDN）研究新进展及未来方向, objectType=article, longId=52422, objectId=d40b52422aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d40b52422aa, replyNumber=0, likeNumber=78, createdTime=2015-10-19, rootId=0, userName=nakerunner, userId=0cd7162, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d40b52422aa, moduleTitle=Symplicity HTN-3 后时代：经导管去肾交感神经术（RDN）研究新进展及未来方向, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d40b52422aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1941528, encodeId=d1fd1941528ce, content=<a href='/topic/show?id=64c94e75a3' target=_blank style='color:#2F92EE;'>#City#</a>, objectTitle=BMJ：偏倚误导——来自Symplicity HTN-3的警示, objectType=article, longId=32283, objectId=ae6b3228332, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae6b3228332, replyNumber=0, likeNumber=80, createdTime=2014-09-13, rootId=0, userName=nakerunner, userId=0cd7162, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae6b3228332, moduleTitle=BMJ：偏倚误导——来自Symplicity HTN-3的警示, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae6b3228332)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1941527, encodeId=80f9194152ebc, content=<a href='/topic/show?id=64c94e75a3' target=_blank style='color:#2F92EE;'>#City#</a>, objectTitle=CIT 2014：SYMPLICITY HTN-3后时代，去肾神经治疗顽固性高血压路在何方？, objectType=article, longId=31828, objectId=0a0131828b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a0131828b0, replyNumber=0, likeNumber=89, createdTime=2014-06-13, rootId=0, userName=nakerunner, userId=0cd7162, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a0131828b0, moduleTitle=CIT 2014：SYMPLICITY HTN-3后时代，去肾神经治疗顽固性高血压路在何方？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a0131828b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1941530, encodeId=c3441941530b3, content=<a href='/topic/show?id=64c94e75a3' target=_blank style='color:#2F92EE;'>#City#</a>, objectTitle=OCC 2014：SYMPLICITY HTN-3研究失败，肾去神经消融术并未终结——访高血压论坛坛主高平进教授, objectType=article, longId=36761, objectId=806636e61bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=806636e61bd, replyNumber=0, likeNumber=101, createdTime=2015-02-03, rootId=0, userName=nakerunner, userId=0cd7162, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=806636e61bd, moduleTitle=OCC 2014：SYMPLICITY HTN-3研究失败，肾去神经消融术并未终结——访高血压论坛坛主高平进教授, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=806636e61bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1941529, encodeId=88b019415296c, content=<a href='/topic/show?id=64c94e75a3' target=_blank style='color:#2F92EE;'>#City#</a>, objectTitle=ACC 2014：解析SYMPLICITY HTN-3研究结果, objectType=article, longId=32549, objectId=c62132549a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c62132549a5, replyNumber=0, likeNumber=90, createdTime=2014-04-01, rootId=0, userName=nakerunner, userId=0cd7162, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c62132549a5, moduleTitle=ACC 2014：解析SYMPLICITY HTN-3研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c62132549a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1941526, encodeId=9b2319415268d, content=<a href='/topic/show?id=64c94e75a3' target=_blank style='color:#2F92EE;'>#City#</a>, objectTitle=经导管双侧肾动脉消融对顽固性高血压疗效存疑（SYMPLICITY HTN-3研究）, objectType=article, longId=29290, objectId=d0a22929081, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d0a22929081, replyNumber=0, likeNumber=73, createdTime=2014-05-29, rootId=0, userName=nakerunner, userId=0cd7162, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d0a22929081, moduleTitle=经导管双侧肾动脉消融对顽固性高血压疗效存疑（SYMPLICITY HTN-3研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d0a22929081)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1941525, encodeId=62f71941525ed, content=<a href='/topic/show?id=64c94e75a3' target=_blank style='color:#2F92EE;'>#City#</a>, objectTitle=CAFS 2013：Ensite Velocity系统在持续性房颤的消融治疗中的应用, objectType=article, longId=22458, objectId=b8642245899, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8642245899, replyNumber=0, likeNumber=93, createdTime=2014-05-10, rootId=0, userName=nakerunner, userId=0cd7162, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8642245899, moduleTitle=CAFS 2013：Ensite Velocity系统在持续性房颤的消融治疗中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8642245899)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

City

2020-05-29

nakerunner (审核中...)

前往app查看评论内容

#City#

Bioelectricity:电磁场可阻碍乳腺癌转移扩散!

2021-10-02

nakerunner (审核中...)

前往app查看评论内容

#City#

City of Hope与Israelita Albert Einstein签署协议以推动拉美地区的癌症治疗

2021-07-11

nakerunner (审核中...)

前往app查看评论内容

#City#

City of Hope正在招募患者进行HPV相关癌症的人体T细胞试验

2019-09-27

nakerunner (审核中...)

前往app查看评论内容

#City#

礼来的GLP-1受体激动剂Trulicity，获得FDA批准用于降低心血管风险

2020-11-03

nakerunner (审核中...)

前往app查看评论内容

#City#

A novel Ruthenium(II) polypyridyl complex induces cytotoxicity, cell cycle arrest, apoptosis and DNA

2018-05-24

nakerunner (审核中...)

前往app查看评论内容

#City#

ADA 2016：礼来每周一次降糖药Trulicity（度拉鲁肽）联合甘精胰岛素显著改善2型糖尿病患者血糖控制

2016-12-11

nakerunner (审核中...)

前往app查看评论内容

#City#

Symplicity HTN-3 后时代：经导管去肾交感神经术（RDN）研究新进展及未来方向

2015-10-19

nakerunner (审核中...)

前往app查看评论内容

#City#

BMJ：偏倚误导——来自Symplicity HTN-3的警示

2014-09-13

nakerunner (审核中...)

前往app查看评论内容

#City#

CIT 2014：SYMPLICITY HTN-3后时代，去肾神经治疗顽固性高血压路在何方？

2014-06-13

nakerunner (审核中...)

前往app查看评论内容

#City#

OCC 2014：SYMPLICITY HTN-3研究失败，肾去神经消融术并未终结——访高血压论坛坛主高平进教授

2015-02-03

nakerunner (审核中...)

前往app查看评论内容

#City#

ACC 2014：解析SYMPLICITY HTN-3研究结果

2014-04-01

nakerunner (审核中...)

前往app查看评论内容

#City#

经导管双侧肾动脉消融对顽固性高血压疗效存疑（SYMPLICITY HTN-3研究）

2014-05-29

nakerunner (审核中...)

前往app查看评论内容

#City#

CAFS 2013：Ensite Velocity系统在持续性房颤的消融治疗中的应用

2014-05-10

科室
- - 订阅+
  - 更多科室
工具
服务